Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - alendronate sodium, quantity: 91.35 mg (equivalent: alendronic acid, qty 70 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; macrogol 8000; carrageenan; magnesium stearate - treatment of osteoporosis, including glucocorticoid induced osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - piperacillin sodium, quantity: 4.253 g; tazobactam sodium, quantity: 0.547 g (equivalent: tazobactam, qty 0.5 g) - injection, powder for - excipient ingredients: - pipertaz sandoz is used to treat serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: 1) lower respiratory tract infections; 2) urinary tract infections (complicated and uncomplicated); 3) intra-abdominal infections; 4) skin and skin structure infections; 5) bacterial septicaemia; 6) gynaecological infections. children under the age of 12 years: in hospitalised children aged 2 to 12 years, pipertaz sandoz is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in children below the age of 2 years. while pipertaz sandoz (piperacillin/tazobactam) is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin-resistant organisms. appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibility to pipertaz sandoz (piperacillin/tazobactam). therapy with pipertaz sandoz (piperacillin/tazobactam), however, may be initiated before results of each test are known when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above, however, once these results are available, appropriate therapy should be continued. in serious infections, presumptive therapy with pipertaz sandoz (piperacillin/tazobactam) may be initiated before susceptibility test results are available. combination therapy with pipertaz sandoz (piperacillin/tazobactam) and aminoglycosides may be used int he treatment of serious infections caused by pseudomonas aeruginosa. both drugs shold be used in full therapeutic doses. as soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - tamoxifen citrate, quantity: 30.4 mg (equivalent: tamoxifen, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; titanium dioxide; microcrystalline cellulose; povidone; hypromellose; macrogol 4000; magnesium stearate; sodium starch glycollate - treatment of breast cancer. ? tamoxifen sandoz is indicated for the treatment of breast cancer.,primary reduction of breast cancer risk ? tamoxifen sandoz is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amiodarone hydrochloride, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; colloidal anhydrous silica; povidone; maize starch - severe cases of tachyarrhythmias (e.g wolf-parkinson-white syndrome; supraventricular, nodal and ventricular tachycardias; atrial flutter and fibrillation; ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg thyroid function, chest x-ray, ophthalmological examination, hepatic function) during the entire course of therapy and for several months after discontinuation.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate dihydrate; hyprolose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; calcium hydrogen phosphate dihydrate; lactose monohydrate; crospovidone; hyprolose; magnesium stearate; microcrystalline cellulose - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; propylene glycol; hypromellose; sodium starch glycollate; maize starch; purified talc; macrogol 6000; magnesium stearate; titanium dioxide; povidone - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: magnesium stearate; macrogol 6000; purified talc; colloidal anhydrous silica; povidone; titanium dioxide; sodium starch glycollate; propylene glycol; hypromellose; maize starch - treatment of type 2 diabetes mellitus in adults, particularly in over weight patients, when dietary management and exercise alone, does not result in adequate glycaemic control. metformin may be used as initial treatment, or in sulphonylurea failures, either alone or in combination with a sulphonylurea and other oral agents or as adjuvant therapy in insulin dependent diabetes.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sotalol hydrochloride, quantity: 80 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; hyprolose; magnesium stearate; colloidal anhydrous silica - prevention and treatment of supraventricular and ventricular arrhythmias.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - sotalol hydrochloride, quantity: 160 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; hyprolose; sodium starch glycollate; colloidal anhydrous silica; magnesium stearate - prevention and treatment of supraventricular and ventricular arrhythmias.